Charmaine Rock

Mrs. Charmaine Rock

The Ritchie Centre, Hudson Institute of Medical Research
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
CRCharmaine Rock
Charmaine Rock
TWTegan A. White
Tegan A. White
BPBeth R. Piscopo
Beth R. Piscopo
ASAmy Sutherland
Amy Sutherland
Suzanne L MillerSuzanne L Miller
Suzanne L Miller
Beth J. AllisonBeth J. Allison
Beth J. Allison
Fetal growth restriction (FGR) is a common complication of pregnancy, resulting in a fetus that fails to reach its genetically determined growth potential. Whilst the fetal cardiovascular response to acute hypoxia is well established, the fetal defence to chronic hypoxia is not well understood due to experiment constraints. Growth restriction results primarily from reduced oxygen and nutrient supply to the developing fetus, resulting in chronic hypoxia. The fetus adapts to chronic hypoxia by redistributing cardiac output via brain sparing in an attempt to preserve function in the developing brain. This review highlights the impact of brain sparing on the developing fetal cardiovascular and cerebrovascular systems, as well as emerging long-term effects in offspring that were growth restricted at birth. Here, we explore the pathogenesis associated with brain sparing within the cerebrovascular system. An increased understanding of the mechanistic pathways will be critical to preventing neuropathological outcomes, including motor dysfunction such as cerebral palsy, or behaviour dysfunctions including autism and attention-deficit/hyperactivity disorder (ADHD).

1 December 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
CRCharmaine Rock
Charmaine Rock
TWTegan A. White
Tegan A. White
BPBeth R. Piscopo
Beth R. Piscopo
ASAmy E. Sutherland
Amy E. Sutherland
YPYen Pham
Yen Pham
Beth J. AllisonBeth J. Allison
Beth J. Allison
Our findings provide novel insight into the potential mechanisms that program for cardiovascular dysfunction in growth-restricted neonates as our growth-restricted lambs exhibited a progressive decline in endothelium-dependent vasodilation in the femoral artery between birth and 4 wk of age. Subsequent analyses indicated that this reduction in vasodilatory capacity is likely to be mediated by the prostanoid pathway and prostanoids could be a potential target for therapeutic interventions for fetal growth restriction (FGR).

15 November 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
CRCharmaine Rock
Charmaine Rock
Suzanne L MillerSuzanne L Miller
Suzanne L Miller
Beth J. AllisonBeth J. Allison
Beth J. Allison
Fetal growth restriction (FGR) increases the risk of cardiovascular disease. There are currently no treatment options available; however, antioxidants have shown potential to improve cardiovascular deficits associated with FGR. This systematic review aimed to determine whether antenatal antioxidant intervention can effectively protect the developing cardiovascular system in FGR. We searched for interventional studies that used an antenatal antioxidant intervention to improve cardiac and/or vascular outcomes in FGR published between 01/1946 and 09/2024 using MEDLINE and Embase (PROSPERO: CRD42024503756). The risk of bias was assessed with SYRCLE. The studies were assessed for cardiovascular protection based on the percentage of cardiac and/or vascular deficits that were restored with the antioxidant treatment. Studies were characterised as showing strong cardiovascular protection (≥50% restoration), mild cardiovascular protection (>0% but <50% restoration), an antioxidant-only effect (this did not include control group which showed a change with antioxidant intervention compared to FGR) or no cardiovascular protection (0% restoration). Thirty-eight publications met the inclusion criteria, encompassing 43 studies and investigating 15 antioxidant interventions. Moreover, 29/43 studies (71%) reported the restoration of at least one cardiac or vascular deficit with antioxidant intervention, and 21/43 studies (51%) were classified as strong cardiovascular protection. An ex vivo analysis of the arterial function in seven studies revealed endothelial dysfunction in growth-restricted offspring and antioxidant interventions restored the endothelial function in all cases. Additionally, four studies demonstrated that antioxidants reduced peroxynitrite-mediated oxidative stress. Notably, only 13/43 studies (32%) delayed antioxidant administration until after the induction of FGR. Antenatal antioxidant interventions show promise for providing cardiovascular protection in FGR. Melatonin was the most frequently studied intervention followed by nMitoQ, vitamin C and N-acetylcysteine, all of which demonstrated a strong capacity to reduce oxidative stress and improve nitric oxide bioavailability in the cardiovascular system of growth-restricted offspring; however, this systematic review highlights critical knowledge gaps and inconsistencies in preclinical research, which hinder our ability to determine which antioxidant treatments are currently suitable for clinical translation.

13 November 2025 in The Journal of Physiology
Verified
Journal Article
Open access
CRCharmaine Rock
Charmaine Rock
TWTegan A. White
Tegan A. White
BPBeth R. Piscopo
Beth R. Piscopo
ASAmy Sutherland
Amy Sutherland
YPYen Pham
Yen Pham
Beth J. AllisonBeth J. Allison
Beth J. Allison
Fetal growth restriction (FGR) increases the risk of cardiovascular disease. FGR is linked to placental insufficiency and fetal hypoxemia, leading to oxidative stress and inflammation, which collectively influence the developmental programming of cardiovascular disease. This study assessed whether melatonin (MLT), a potent antioxidant and anti‐inflammatory agent, could prevent cardiovascular deficits associated with FGR. Placental insufficiency was induced in ewes at 89 days of gestational age (dGA, term 148 dGA). Ewes were randomly allocated to control, FGR or FGR+MLT ( i.v. , 15 mg day −1 , from 95 dGA to birth) groups. Lambs were delivered preterm at 136 dGA and assessed as newborn (24 h) and 4‐week‐old lambs. Vascular function was determined in femoral arteries using in vitro wire myography and vascular morphology as assessed in carotid and femoral arteries. Newborn FGR lambs were ∼30% smaller than control lambs with an increased brain‐to‐body weight ratio, indicative of brain sparing. Femoral endothelial function declined between ∼24 h after birth and 4 weeks in FGR lambs. By contrast, femoral arteries from newborn FGR+MLT lambs displayed transient endothelial dysfunction that improved by 4 weeks. However, these arteries showed elevated levels of oxidative stress and inflammation. Despite improving endothelial function, melatonin also disrupted the brain‐sparing response in FGR lambs. Furthermore, by 4 weeks of age, melatonin treatment led to heightened oxidative stress and inflammatory markers in the peripheral vasculature, suggesting a potential trade‐off between vascular benefits and systemic maladaptation. These findings highlight the complexity of melatonin's effects on the cardiovascular system and underscore the need for careful evaluation of its long‐term safety and efficacy before clinical translation. image Key points: Fetal growth restriction (FGR) significantly increases the lifelong risk of cardiovascular disease, and there are currently no targeted treatments to mitigate these risks. This study follows growth‐restricted lambs from birth to 4 weeks of age (comparable to a 1‐year‐old human in terms of cardiovascular function) to characterise how FGR affects vascular development over time. FGR lambs exhibited progressive endothelial dysfunction in the femoral artery, but antenatal melatonin treatment restored endothelial function long‐term despite the presence of vascular oxidative stress and inflammation. The brain‐sparing response is a key adaptive mechanism for fetal survival, yet melatonin appears to dampen this response, highlighting the need for further investigation into its broader physiological effects.

24 July 2025 in Experimental Neurology
Verified
Journal Article
Open access
ARAbdul Razak
Abdul Razak
ASAmy Sutherland
Amy Sutherland
YPYen Pham
Yen Pham
TYTamara Yawno
Tamara Yawno
INIlias Nitsos
Ilias Nitsos
CMCourtney McDonald
Courtney McDonald
Preterm brain injury involves persistent inflammation, making it a potential therapeutic target. Current large animal models focus on short-term outcomes, limiting understanding of long-term effects. We developed an ovine model of inflammation-induced preterm brain injury to assess long-term neuropathology at an age equivalent to early cerebral palsy diagnosis in human infants. Fetal sheep were instrumented at gestational day (d) 90-91 (term is 148d): one group received lipopolysaccharide (LPS 200 ng; n = 9) on 96d, 97d, and 98d (0.65 gestation, ∼25-26 weeks human brain development), and a control group received saline (n = 8). Birth was induced on 138d, and lambs were euthanised within 24 h of birth. Brains were evaluated for white matter injury, microglial/macrophage activation and astrogliosis in the subcortical (SCWM), periventricular (PVWM), and cortical (CWM) white matter, subventricular zone (SVZ), and corpus callosum (CC). Antenatal LPS administration was associated with significant persistent microglial/macrophage activation in the PVWM (P = 0.04), SCWM (P = 0.01), and CWM (P = 0.006). Furthermore, LPS exposure was associated with reduced oligodendrocyte cell number in the PVWM (P = 0.02), SCWM (P = 0.001), and CWM (P = 0.0001), and reduced myelination in CWM (CNPase, P < 0.0001 and MBP, P = 0.04) and SVZ (MBP, P = 0.05). No difference in astrogliosis or microhaemorrhages was observed. We demonstrated that in a large animal model of inflammation-induced intrauterine preterm brain injury, long-term persistent inflammation occurs, along with significant white matter injury, including loss of oligodendrocytes and reduced myelination in multiple white matter regions. This model paves the way for long-term evaluation of promising therapeutics and behavioral assessment in this clinically relevant model of persistent preterm brain injury.

1 December 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
ZAZahrah Azman
Zahrah Azman
CRCharmaine Rock
Charmaine Rock
ASAmy E. Sutherland
Amy E. Sutherland
VZValerie A. Zahra
Valerie A. Zahra
YPYen Pham
Yen Pham
Beth J. AllisonBeth J. Allison
Beth J. Allison
Within 24 h of birth, growth-restricted (FGR) newborn lambs exhibited altered lipid and serotonin metabolites, suggesting disrupted postnatal cardiac metabolic adaptation. Despite upregulation of the fatty acid transporter gene SLC27A6, with other fatty acid oxidation genes remaining largely unchanged, reductions in lipid and carnitine metabolites indicate potential impairments in fatty acid utilization. Decreased serotonin bioavailability further suggests metabolic reprogramming in FGR hearts, highlighting the need for future studies on the implications for postnatal cardiac function.